CRO Solutions for Oral Solid Dosage Manufacturers

Oral solid dosage forms, including tablets and capsules, dominate the global pharmaceutical market due to OSD convenience and cost-effectiveness. However, manufacturers face numerous challenges in bringing these products to market, including navigating bioequivalence studies, adhering to GMP requirements, and meeting evolving regulatory expectations. Thus, partnering with a Contract Research Organization (CRO) like Zenovel is essential, as it provides integrated solutions encompassing Good Clinical Practice (GCP), GMP, and Regulatory Affairs to support the entire product lifecycle from development to commercialization.

The Unique Challenges Facing OSD Manufacturers

 Regulatory Expectations:

Regulatory agencies globally, such as the FDA, EMA, and WHO, are increasingly focusing on data integrity, quality management systems, and risk-based oversight. For manufacturers of oral solid dosage forms (OSD), this necessitates proving compliance throughout the entire development continuum, not merely in manufacturing.

 Bioequivalence:

For generic OSD manufacturers, demonstrating bioequivalence is essential for approval. Bioequivalence (BE) studies show that generic drugs release active ingredients similarly to brand-name drugs, measured by pharmacokinetic parameters like AUC and Cmax within 80–125% relative to the reference. Without bioequivalence, generics cannot substitute brand-name drugs, affecting companies’ affordability and availability.

 GMP Compliance:

GMP influences all phases of OSD product development, guaranteeing product quality through controlled manufacturing, validation, change management, and documentation. Insufficient GMP frameworks can lead to delays during technology transfer, process validation, stability studies, and regulatory submissions.

 The Documentation Expectations

OSD manufacturers need to generate comprehensive documentation during the development lifecycle, including clinical study protocols, reports, CMC documentation, and regulatory submissions. Minor inconsistencies can lead to review delays, regulatory queries, or requests for additional information.

Zenovel Offers CRO Solutions to OSD Manufacturers

Zenovel specializes in high-impact solutions in the pharmaceutical industry, focusing on Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Regulatory Affairs. With extensive industry experience and a global presence in India, the USA, Canada, and the EU, Zenovel offers unmatched expertise in its engagements.

 GCP Services for Clinical Development Excellence

Zenovel provides comprehensive clinical trial services across all phases (I to IV), including bioequivalence (BE) and pharmacokinetic (PK) studies tailored to client needs. Key capabilities feature Risk-Based Monitoring (RBM) for efficient trial processes and enhanced patient safety, PK-Stat Review for converting data into regulatory evidence, and independent Clinical Monitoring to ensure GCP adherence. With GCP monitoring engagements and extensive experience in trial oversight, Zenovel also assists in CRO setup, process optimization, and regulatory compliance.

Zenovel provides a comprehensive suite of clinical trial services spanning Phase I to Phase IV, which includes patient-focused bioequivalence (BE) and pharmacokinetic (PK) studies, along with customized therapeutic research to fulfill unique client requirements.